All In Biotech

Drug Trial Radar · NCT02338960

2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder

Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)

Last checked: Nov 19, 2026Latest source record: Jan 28, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 714 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

714

Actual

Start

Jan 2015

Primary completion

Aug 2016

Study completion Jun 29, 2017

Sponsor

Lead sponsor
Palatin Technologies, IncIndustry
Sponsor type
Industry
Collaborators
AMAG Pharmaceuticals, Inc.
First posted
Jan 15, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an optional Open-label Extension to evaluate the efficacy of bremelanotide (BMT), administered subcutaneously (SC) on an as needed basis for the treatment of HSDD (with or without decreased arousal) in premenopausal females.

Conditions

  • Hypoactive Sexual Desire Disorder

Interventions

  • BremelanotideDrug

    A melanocortin agonist and synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulating hormone)

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy of a Fixed Dose of Bremelanotide as Measured by FSFI (Question Q1 and Q2), 28-day Recall.Time frame: 8 weeks baseline plus 24 weeks (Main Study), 52 Weeks (OLE)
  2. Efficacy of a Fixed Dose of Bremelanotide as Measured by FSDS-DAO (Item 13)Time frame: 8 weeks baseline plus 24 weeks (Main Study), 52 Weeks (OLE)

Locations

91 sites in 2 countries. Site status is shown where the registry gives one.

  • Palatin Clinical Site 242

    Birmingham, Alabama

  • Palatin Clinical Site 218

    Phoenix, Arizona

  • Palatin Clinical Site 254

    Tucson, Arizona

  • Palatin Clinical Site 207

    Hot Springs, Arkansas

  • Palatin Clinical Site 258

    Beverly Hills, California

  • Palatin Clinical Site 256

    Garden Grove, California

  • Palatin Clinical Site 291

    Los Angeles, California

  • Palatin Clinical Site 270

    Oakland, California

  • Palatin Clinical Site 210

    San Diego, California

  • Palatin Clinical Site 251

    San Diego, California

  • Palatin Clinical Site 272

    Sherman Oaks, California

  • Palatin Clinical Site 253

    Tarzana, California

  • Palatin Clinical Site 212

    Denver, Colorado

  • Palatin Clinical Site 219

    Denver, Colorado

  • Palatin Clinical Site 243

    Lakewood, Colorado

  • Palatin Clinical Site 211

    New London, Connecticut

  • Palatin Clinical Site 229

    Waterbury, Connecticut

  • Palatin Clinical Site 202

    Washington D.C., District of Columbia

  • Palatin Clinical Site 204

    Aventura, Florida

  • Palatin Clinical Site 273

    Coral Gables, Florida

  • Palatin Clinical Site 203

    Fort Myers, Florida

  • Palatin Clinical Site 255

    Gainesville, Florida

  • Palatin Clinical Site 266

    Gainesville, Florida

  • Palatin Clinical Site 224

    Jupiter, Florida

  • Palatin Clinical Site 250

    Orlando, Florida

  • Palatin Clinical Site 261

    Oviedo, Florida

  • Palatin Clinical Site 260

    Pinellas Park, Florida

  • Palatin Clinical Site 236

    West Palm Beach, Florida

  • Palatin Clinical Site 248

    Alpharetta, Georgia

  • Palatin Clinical Site 263

    Atlanta, Georgia

  • Palatin Clinical Site 288

    Addison, Illinois

  • Palatin Clinical Site 252

    Chicago, Illinois

  • Palatin Clinical Site 201

    Chicago, Illinois

  • Palatin Clinical Site 277

    Indianapolis, Indiana

  • Palatin Clinical Site 247

    Prairie Village, Kansas

  • Palatin Clinical Site 286

    Paducah, Kentucky

  • Palatin Clinical Site 279

    Lake Charles, Louisiana

  • Palatin Clinical Site 281

    Metairie, Louisiana

  • Palatin Clinical Site 257

    Annapolis, Maryland

  • Palatin Clinical Site 222

    Lutherville, Maryland

Showing 40 of 91 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.